Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Salutsantjoan     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon


My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com




Saturday, April 30, 2016

Mechanical circulatory support

Biomed Central logo
Shekar K, Gregory S and Fraser J. Critical Care 2016; 20:66 - Published: 16 March 2016
DOI: 10.1186/s13054-016-1235-3
This review highlights the spectrum of available therapies for acute and chronic heart failure patients and circulatory shock in general. The flexible nature of MCS configurations allows for an individualized approach driven by the ultimate goal of achieving organ recovery or bridging to long‐term options. Intensivists, when faced with severe cardiac failure, especially in younger patients, may have to consider MCS as a viable option and initiate timely referrals. Similarly in patients with chronic heart failure, timely insertion of long-term VADs prior to development of irreversible end‐organ dysfunction will minimize postoperative morbidity and eliminate the need for short‐term temporary bridging mechanical support. Some patients will need short‐term mechanical right heart support with a temporary RVAD and in others a long‐term BiVAD may be inevitable and customized implantable RVADs may become a reality in future. Both VAD and total artificial heart technology will see many more refinements with time and it is difficult to predict which of these devices will prove to be a perfect bridge to heart transplant or destination. Whilst these technologies may seem excessively complex and expensive, this was once said of dialysis. In the current era, in an appropriately resourced setting, no eligible patient should die on maximal medical therapy without MCS being considered."